Hemagglutination inhibition of Cromer blood group antibodies with soluble recombinant decay-accelerating factor

被引:20
作者
Daniels, GL
Green, CA
Powell, RM
Ward, T
机构
[1] Bristol Inst Transfus Sci, Bristol BS10 5ND, Avon, England
[2] Univ Reading, Sch Anim & Microbial Sci, Reading RG6 2AH, Berks, England
关键词
D O I
10.1046/j.1537-2995.1998.38498257370.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Cromer blood group antigens are located on decay-accelerating factor (DAF, CD55), which contains four short consensus repeats (SCRs). Cromer system antibodies may be of clinical significance in blood transfusion. STUDY DESIGN AND METHODS: Soluble recombinant DAF (srDAF) constructs, consisting of all four SCRs or of only two SCRs, were expressed in the yeast Pichia pastoris. They are used in hemagglutination-inhibition tests with Cromer system antibodies and with DAF-specific monoclonal antibodies. RESULTS: The srDAF inhibited hemagglutination by all Cromer system alloantibodies in undiluted serum. Antibodies to antigens of other blood group systems were not inhibited by the srDAF. Hemagglutination-inhibition tests with domain-deleted srDAF showed that UMC is on SCR-4 and confirmed that Tc-a, (TcTcb)-Tc-a, and WESb are on SCR-1;Dr(a) is on SCR-3; and Cr-a is on SCR-4. CONCLUSIONS: Hemagglutination inhibition with srDAF is useful in the recognition of antibodies that belong to the Cromer blood group system and facilitates pretransfusion testing. This use of domain-deleted srDAF provides an easy method of determining epitope location on DAF and is an aid to more precise identification of Cromer system antibodies.
引用
收藏
页码:332 / 336
页数:5
相关论文
共 19 条
[1]  
Brodbeck WG, 1996, J IMMUNOL, V156, P2528
[2]  
COYNE KE, 1992, J IMMUNOL, V149, P2906
[3]  
DANIELS G, 1995, HUMAN BLOOD GROUPS, P567
[4]   ANOTHER EXAMPLE OF ANTI-TCA [J].
GORMAN, MI ;
GLIDDEN, HM ;
BEHZAD, O .
TRANSFUSION, 1981, 21 (05) :579-579
[5]   ADSORPTION OF ANTI-CRA BY HUMAN PLATELET CONCENTRATES [J].
JUDD, WJ ;
STEINER, EA ;
MISKE, V .
TRANSFUSION, 1991, 31 (03) :286-286
[6]   Molecular modeling and mechanism of action of human decay-accelerating factor [J].
KuttnerKondo, L ;
Medof, ME ;
Brodbeck, W ;
Shoham, M .
PROTEIN ENGINEERING, 1996, 9 (12) :1143-1149
[7]   TCA - A HIGH-FREQUENCY BLOOD-GROUP ANTIGEN [J].
LAIRDFRYER, B ;
DUKES, CV ;
LAWSON, J ;
MOULDS, JJ ;
WALKER, EM ;
GLASSMAN, AB .
TRANSFUSION, 1983, 23 (02) :124-127
[8]  
Lublin D. M., 1997, Transfusion (Bethesda), V37, p102S
[9]   DECAY-ACCELERATING FACTOR - BIOCHEMISTRY, MOLECULAR-BIOLOGY, AND FUNCTION [J].
LUBLIN, DM ;
ATKINSON, JP .
ANNUAL REVIEW OF IMMUNOLOGY, 1989, 7 :35-58
[10]   DR(A-) POLYMORPHISM OF DECAY ACCELERATING FACTOR - BIOCHEMICAL, FUNCTIONAL, AND MOLECULAR CHARACTERIZATION AND PRODUCTION OF ALLELE-SPECIFIC TRANSFECTANTS [J].
LUBLIN, DM ;
THOMPSON, ES ;
GREEN, AM ;
LEVENE, C ;
TELEN, MJ .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (06) :1945-1952